Reliability of Sensor-Derived Measurements of the SENSorized Fugl-Meyer (FMA) in Subjects with Stroke Outcomes

NCT06893367 | Not Yet Recruiting

• 1 other identifier: FMA-SENS
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

This study will be conducted at a single research center, the main objective of the study will be to evaluate the efficacy, safety, and accuracy of a medical device that has not yet been commercialized; therefore, it is still under development or testing and is not yet available for private use and is not for profit (nonprofit). Fifty participants will be recruited from subjects afferent to the outpatient and inpatient neuro-motor rehabilitation clinics of IRCCS Fondazione Don Carlo Gnocchi in Florence, Italy, and afferent to the outpatient and inpatient rehabilitation clinics of Elias University Emergency Hospital in Bucharest, Romania. In detail, it is deemed necessary to collect clinical and instrumental data. The study will be conducted by an interdisciplinary team composed of healthcare professionals and engineers afferent to the Department of Industrial Engineering. Should you decide to participate in the study, a visit to verify the inclusion and exclusion criteria will be primarily conducted. Once the admission criteria have been verified, participants will undergo a series of assessments. The first, involves the administration of some specific sections of the Fugl-Meyer scale (FMA), focusing on the upper extremities. Specifically, the following will be examined: section A for general upper limb function, section B assessing wrist mobility, and finally section D for limb coordination and speed. During this phase, both upper limbs will be assessed, in addition, the first examiner will carefully place sensors on the participants and assign scores to the tests performed, according to the criteria established by the FMA scale. Next, a second assessment (T1) will be conducted, in which a second examiner will be responsible for placing the sensors and recording data only on the most affected side. At a third time, called "T2" and again with at least 15 minutes interval from T1, the first examiner will repeat the same assessments performed in "T1." While performing these assessments, a RealSense camera will be used.

Conditions

Stroke; Sensorimotor Impairment Affecting the Upper Limb; 18 Years and Over

Outcome Measures

Primary Outcomes (3)

• Participants assessed by IMU

  The Fugl-Meyer Assessment (FMA) is obtained with IMU and RealSense cameras. Below are the individual items of the FMA that will be acquired via the experimental kit: * A II. Voluntary movement in synergy: flexor synergy/extensor synergy * A III. Voluntary movement with mixed synergies: hand to lumbar spine/shoulder flexion 0- 90/pronation-supination * A IV. Voluntary movement with reduced or absent synergy: shoulder abduction 0-90/shoulder flexion 90-180/pronation-supination * B I. Wrist: stability at 15° dorsiflexion with elbow 90° * B II. Wrist: repeated dorsiflexion with elbow 90° * B III. Wrist: Stability at 15° dorsiflexion with elbow at 0° * B IV. Wrist: repeated dorsiflexion with elbow at 0° * D. Coordination/Speed: tremor * D. Coordination/Speed: dysmetria * D. Coordination/Speed: time

  baseline

• Participants assessed by IMU

  The Fugl-Meyer Assessment (FMA) is obtained with IMU and RealSense cameras. Below are the individual items of the FMA that will be acquired via the experimental kit: * A II. Voluntary movement in synergy: flexor synergy/extensor synergy * A III. Voluntary movement with mixed synergies: hand to lumbar spine/shoulder flexion 0- 90/pronation-supination * A IV. Voluntary movement with reduced or absent synergy: shoulder abduction 0-90/shoulder flexion 90-180/pronation-supination * B I. Wrist: stability at 15° dorsiflexion with elbow 90° * B II. Wrist: repeated dorsiflexion with elbow 90° * B III. Wrist: Stability at 15° dorsiflexion with elbow at 0° * B IV. Wrist: repeated dorsiflexion with elbow at 0° * D. Coordination/Speed: tremor * D. Coordination/Speed: dysmetria * D. Coordination/Speed: time

  at least 15 min from baseline

• Participants assessed by IMU

  The Fugl-Meyer Assessment (FMA) is obtained with IMU and RealSense cameras. Below are the individual items of the FMA that will be acquired via the experimental kit: * A II. Voluntary movement in synergy: flexor synergy/extensor synergy * A III. Voluntary movement with mixed synergies: hand to lumbar spine/shoulder flexion 0- 90/pronation-supination * A IV. Voluntary movement with reduced or absent synergy: shoulder abduction 0-90/shoulder flexion 90-180/pronation-supination * B I. Wrist: stability at 15° dorsiflexion with elbow 90° * B II. Wrist: repeated dorsiflexion with elbow 90° * B III. Wrist: Stability at 15° dorsiflexion with elbow at 0° * B IV. Wrist: repeated dorsiflexion with elbow at 0° * D. Coordination/Speed: tremor * D. Coordination/Speed: dysmetria * D. Coordination/Speed: time

  at least 30 min from baseline

Secondary Outcomes (2)

• Total FMA score

  baseline

• MODIFIED BARTHEL INDEX (mBI)

  baseline

Study Arms (1)

Stroke group

EXPERIMENTAL

each participant will perform the FMA with IMU

Device: IMU and RealSense Cameras

Interventions

IMU and RealSense Cameras DEVICE

Each participant will perform the FMA-sens, with their most affected hand, followed by the FMA-sens with the less affected hand.

Stroke group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• age 18 years or older;
• stroke outcomes with the presence of sensorimotor impairment in the upper limb;
• willingness to participate in the project, with informed consent signed by the person himself or, when necessary, by the support administrator/legal guardian.

You may not qualify if:

• Severe concomitant pathologies that modify the subject's motor framework;
• severe visual and/or hearing impairments that cannot be corrected;
• severe neuropsychological impairments (aphasia, apraxia, other cognitive deficits ) such as to prevent cooperation in administering the scale;
• presence of signs of clinical instability, defined by a score greater than zero on the SIC scale (Clinical Instability Scale).

Sponsors & Collaborators

• Fondazione Don Carlo Gnocchi Onlus: lead
• University of Florence: collaborator
• University of Bucharest: collaborator

Study Sites (1)

IRCCS Fondazione Don Carlo Gnocchi, Firenze

Florence, Italy

Location

MeSH Terms

Conditions

Stroke

Condition Hierarchy (Ancestors)

Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases

Central Study Contacts

Francesca Cecchi

CONTACT

055/73931; fcecchi@dongnocchi.it

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 6, 2025
• First Posted: March 25, 2025
• Study Start: May 1, 2025
• Primary Completion: May 1, 2026
• Study Completion: May 1, 2026
• Last Updated: March 25, 2025

Record last verified: 2025-03

Locations

IT (1)